Efficacy and Mechanistic Evaluation of Hewei Anchang Formula for Overlapping Gastrointestinal Symptoms in Patients With Coexisting Functional Dyspepsia and Diarrhea-Predominant Irritable Bowel Syndrome

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorXiyuan Hospital of China Academy of Chinese Medical Sciences

About this trial

1. To conduct a multicenter, randomized controlled trial across four hospitals to evaluate the efficacy of Hewei Anchang Formula in patients with overlapping gastrointestinal symptoms of functional dyspepsia (FD) and diarrhea-predominant irritable bowel syndrome (IBS-D), characterized by liver-stomach disharmony syndrome and liver stagnation-spleen deficiency syndrome, respectively. By leveraging the holistic regulatory effects of Chinese herbal formulas and the traditional Chinese medicine principle of "treating different diseases with the same therapeutic approach," this study aims to generate high-level evidence for the management of overlapping gastrointestinal symptoms in functional gastrointestinal disorders (FGIDs) and to establish a standardized and scalable therapeutic strategy. 2. To elucidate the potential mechanisms underlying the therapeutic effects of Hewei Anchang Formula on overlapping gastrointestinal symptoms of FD and IBS-D through multiple targets and pathways, with particular emphasis on modulation of the gut microbiota and the neuroendocrine-immune network.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meet the Rome IV diagnostic criteria for both functional dyspepsia (FD) and diarrhea-predominant irritable bowel syndrome (IBS-D).

Meet the diagnostic criteria for liver-stomach disharmony syndrome in FD and liver qi stagnation with spleen deficiency syndrome in IBS-D.

Aged 18-65 years, with no restriction on sex.

Fully informed about the study and voluntarily provide written informed consent. -

Disqualifiers

Severe primary diseases of the cardiovascular, hepatic, renal, hematologic, or respiratory systems, or malignant tumors.

Other organic gastrointestinal diseases, such as peptic ulcer or ulcerative colitis, or systemic diseases that may affect gastrointestinal motility, such as hyperthyroidism or diabetes mellitus.

Current or anticipated continuous use of medications that may affect gastrointestinal function, including prokinetic agents, antidiarrheal agents, antidepressants, anxiolytics, gut microbiota-modulating agents, and antibiotics.

A history of allergy to any study-related medication or a history of severe food allergy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Hewei Anchang Formula Granules

    Drug

    Hewei Anchang Formula granules will be administered orally at a dose of one sachet twice daily for 4 weeks. Each dose will be dissolved in approximately 100 mL of warm water and taken 1 hour after breakfast and dinner.

  • Hewei Anchang Formula Matching Placebo Granules

    Drug

    The matching placebo granules contain 5% Hewei Anchang Formula granules and will be administered orally at a dose of one sachet twice daily for 4 weeks. Each dose will be dissolved in approximately 100 mL of warm water and taken 1 hour after breakfast and dinner.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Hewei Anchang Formula GroupExperimental treatment 1 intervention
Group B: Placebo GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Functional Dyspepsia Symptom Severity Scale Scores

The scale assesses the frequency and severity of four functional dyspepsia symptoms: postprandial fullness, early satiation, epigastric pain, and epigastric burning. For each symptom, frequency is rated on a 5-point scale ranging from 1 (never) to 5 (present throughout the day), and severity is rated on a 4-point scale ranging from 1 (none) to 4 (severe).

Time frame
Baseline (Day 0), Week 2, Week 4, and Week 8
2

Global Impression Scale for Dyspepsia Symptom Relief

Participants will evaluate the overall relief of dyspepsia-related symptoms during the previous 2 weeks using a 7-point scale: 1 = markedly worse, 2 = worse, 3 = slightly worse, 4 = no relief, 5 = slight relief, 6 = marked relief, and 7 = complete relief. Higher scores indicate greater overall symptom relief.

Time frame
Baseline (Day 0), Week 2, Week 4, and Week 8
3

Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) Score

The IBS-SSS assesses abdominal pain severity, the number of days with abdominal pain during a 14-day period, abdominal distension severity, satisfaction with bowel habits, and the extent to which irritable bowel syndrome interferes with daily life. Higher scores indicate greater symptom severity.

Time frame
Baseline (Day 0), Week 2, Week 4, and Week 8

Secondary outcomes

1

Traditional Chinese Medicine Syndrome Score

The Traditional Chinese Medicine syndrome score assesses 15 symptoms: epigastric fullness, epigastric pain, reduced appetite, heartburn or a burning sensation, belching or acid regurgitation, excessive clear salivation, a sensation of obstruction in the throat, thirst without a desire to drink, lower abdominal distension or pain, limb weakness, shortness of breath, disinclination to speak, heaviness of the body and limbs, aversion to cold, and loose stools. Each item is rated from 0 (none) to 3 (severe). The item scores are summed to obtain a total score ranging from 0 to 45, with higher scores indicating greater symptom severity.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, Week 4 ± 3 days, and Week 8 ± 3 days
2

Irritable Bowel Syndrome Quality of Life Questionnaire (IBS-QOL) Score

The IBS-QOL questionnaire used in this study contains 13 items assessing the impact of bowel problems on feelings of helplessness, embarrassment, time spent in the bathroom, health concerns, body image, daily planning, happiness, comfort when discussing bowel problems, frustration, social relationships, food intake, sexual life, and anger. Each item is rated from 0 (not at all) to 4 (completely true), with higher raw scores indicating a greater negative impact of bowel problems on quality of life.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, Week 4 ± 3 days, and Week 8 ± 3 days
3

Patient-Reported Outcome (PRO) Scale Total Score

The 38-item Patient-Reported Outcome scale assesses upper and lower gastrointestinal symptoms, appetite- and eating-related symptoms, body weight, fatigue, sleep, emotional status, social activities, work-related functioning, and fear of gastroscopy. Each item is scored from 0 to 4. The item scores are summed to obtain a total score ranging from 0 to 152, with higher scores indicating a greater symptom burden and greater functional impact.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, Week 4 ± 3 days, and Week 8 ± 3 days
4

36-Item Short Form Health Survey (SF-36) Scores

The SF-36 assesses self-reported general health, changes in health status, physical functioning, limitations in work and daily activities due to physical or emotional health, social functioning, bodily pain, vitality, emotional well-being, and general health perceptions. Scores will be calculated using the item-specific response weights specified in the questionnaire.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, Week 4 ± 3 days, and Week 8 ± 3 days

Other outcomes

1

Fecal Gut Microbiome Metagenomic Profiles

Fecal samples will undergo metagenomic analysis to characterize gut microbial profiles and their changes across the specified sampling time points.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, and Week 4 ± 3 days
2

Blood and Urine Metabolomic Profiles

Blood and urine samples will undergo metabolomic analysis to characterize metabolic profiles and their changes across the specified sampling time points.

Time frame
Baseline (Day 0 ± 3 days), Week 2 ± 3 days, and Week 4 ± 3 days

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Lead sponsor

Shanghai University of Traditional Chinese Medicine

Collaborator

Affiliated Hospital of Nanjing University of Chinese Medicine

Collaborator

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Collaborator

This trial is not recruiting at the moment. You can still explore other options: